देश: सिंगापुर
भाषा: अंग्रेज़ी
स्रोत: HSA (Health Sciences Authority)
CLOBETASONE BUTYRATE
GLAXOSMITHKLINE PTE LTD
D07AD01
0.05% w/w
CREAM
TOPICAL
Prescription Only
GLAXO WELLCOME OPERATIONS
1990-04-30
SINGAPORE PROPOSED PI_CLEAN EUMOVATE TM Clobetasone butyrate QUALITATIVE AND QUANTITATIVE COMPOSITION Clobetasone 17-butyrate 0.05 % w/w PHARMACEUTICAL FORM Cream and Ointment CLINICAL PARTICULARS INDICATIONS Clobetasone butyrate is a topically active corticosteroid with a wide margin of safety. When formulated as EUMOVATE, it is more effective in the treatment of eczemas than preparations containing 1% w/w hydrocortisone, or the less active synthetic steroid preparations that are in common use, yet has little effect on hypothalamic- pituitary-adrenal function. This has been so even when EUMOVATE was applied to adults in large amounts under whole-body occlusion. All topical corticosteroids can cause cutaneous atrophy if grossly misused. However, studies in animal and human models indicate that EUMOVATE and hydrocortisone cause less thinning of the epidermis than the other topical steroids tested. EUMOVATE is suitable for treating the milder forms of eczema, seborrhoeic dermatitis and other steroid responsive skin condition, which do not require the use of a more potent topical corticosteroid. In the more resistant dermatoses, EUMOVATE may be used as maintenance therapy between courses of one of the more active topical steroids. EUMOVATE may be used as treatment for napkin rash, seborrhoeic dermatitis and atopic eczema, reserving the more potent preparations for use in short courses on resistant areas. DOSAGE AND ADMINISTRATION EUMOVATE should be applied to the affected area up to four times a day until improvement occurs, when the frequency of application may be reduced. If the condition worsens or does not improve within four weeks, treatment and diagnosis should be re-evaluated. Therapy with topical corticosteroids should be gradually पूरा दस्तावेज़ पढ़ें